Rules-Based Medicine, EMD To Co-Develop Protein Multiplex Assays for xMAP | GenomeWeb
NEW YORK (GenomeWeb News) - Rules-Based Medicine and EMD Chemicals said today that they are partnering to develop and distribute immunoassay products for use on Luminex’s xMAP platform.
 
Under the terms of the agreement, biomarker testing firm RBM is providing EMD, a subsidiary of Germany’s Merck KGaA, exclusive distribution rights to its catalog of quantitative protein multiplex assays.
 
EMD will market RBM’s testing content in co-branded multi-analyte kits under its Novagen brand.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.